CRNX
Crinetics Pharmaceuticals Inc

1,453
Mkt Cap
$4.07B
Volume
972,509.00
52W High
$60.34
52W Low
$24.10
PE Ratio
-9.46
CRNX Fundamentals
Price
$41.97
Prev Close
$42.90
Open
$43.28
50D MA
$40.91
Beta
1.15
Avg. Volume
1.45M
EPS (Annual)
-$3.69
P/B
3.78
Rev/Employee
$2,377.57
Loading...
Loading...
News
all
press releases
Los Angeles Capital Management LLC Purchases Shares of 9,433 Crinetics Pharmaceuticals, Inc. $CRNX
Los Angeles Capital Management LLC acquired a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the second quarter, according to its most recent disclosure with...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by Candriam S.C.A.
Candriam S.C.A. raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 41.9% in the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·6d ago
News Placeholder
What is HC Wainwright's Forecast for CRNX FY2029 Earnings?
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities research analysts at HC Wainwright reduced their FY2029 earnings estimates for shares of Crinetics Pharmaceuticals in a report...
MarketBeat·11d ago
News Placeholder
Crinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS
Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.38) earnings per share for the quarter, missing analysts...
MarketBeat·11d ago
News Placeholder
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down on Disappointing Earnings
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down on Disappointing Earnings...
MarketBeat·12d ago
News Placeholder
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $108.00 Price Target at Citizens Jmp
Citizens Jmp reduced their price objective on Crinetics Pharmaceuticals from $143.00 to $108.00 and set a "market outperform" rating for the company in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
Key PointsThe biotech unveiled its third-quarter results...
Nasdaq News: Markets·13d ago
News Placeholder
Dana Pizzuti Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 5,000 shares of the firm's stock in a transaction dated Monday, November 3rd. The stock was sold at an...
MarketBeat·14d ago
News Placeholder
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.66% and -94.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Crinetics Pharmaceuticals Inc Q3 Loss Increases, Misses Estimates
(RTTNews) - Crinetics Pharmaceuticals Inc (CRNX) reported Loss for its third quarter that increased from the same period last year and missed the Street estimates...
Nasdaq News: Markets·14d ago

Latest CRNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.